PainChek Limited Overview
PainChek is a micro-cap Australian digital-health company. It sells a regulator-cleared, AI-enabled smartphone medical device for assessing pain in people who cannot reliably self-report it, chiefly residents with moderate-to-severe dementia in aged care. The app combines automated facial analysis of pain-related facial action units with structured caregiver observation and a Numerical Rating Scale. It is sold mainly as a per-bed software subscription to residential aged care, home care and disability providers. At 30 June 2026, PainChek had 90,198 implemented licences, A$4.46m of implemented ARR, 1,990 active customer sites and 21.38m cumulative assessments, mainly across Australia/New Zealand and the UK. FDA De Novo clearance in October 2025 made PainChek Adult the first regulated device of its kind in the United States. The company is now trying to convert that access into US revenue through Sabra Health Care REIT and other channels. It remains loss-making (FY2026 net loss A$8.94m) and depends on external funding.
Company's own description (FY2026 Annual Report, Directors' Report). PainChek describes itself as a regulator-cleared, AI-enabled medical device that supports pain assessment for people who cannot reliably self-report their pain, while also enabling assessment of people who can. The financial statements describe its principal activity as the development and commercialisation of mobile medical device applications that provide pain assessment for individuals unable to communicate with their carers. Management characterises FY2026 as the year PainChek began "shifting from building market access to converting that access into implemented recurring revenue."
What the product does. A carer uses a smartphone or tablet to capture a short video of the resident's face. PainChek's facial-analysis AI detects facial action units associated with pain. The carer then completes digital checklists of non-facial pain behaviours, such as vocalisation, movement and behaviour. The app combines both inputs into an overall pain score, which is documented at the point of care and synchronised to a cloud portal and the PainChek Analytics reporting suite. PainChek Universal adds the Numerical Rating Scale (NRS), so the same tool can be used for residents who can self-report and those whose ability fluctuates. In the US the device is cleared as a prescription, adjunctive tool. It is not a stand-alone diagnostic or prognostic tool (FDA DEN240073 classification).
Business model.
Revenue model mix. PainChek is essentially a pure subscription business: about 96% subscription and about 4% services. There is no hardware, licensing-to-third-party or royalty revenue (FY2026 Note 3).
Value-chain position. PainChek sits at the clinical-application layer. It does not own care facilities or devices; customers use their own smartphones and tablets. It relies on cloud hosting and on integrations with clinical/electronic health record platforms, citing about 40 integration partnerships (January 2026 business update). Cost of providing services, A$1.10m in FY2026, comprises customer implementation and training ("Customer Excellence"), cloud hosting and integration fees paid to partners.
Customer types and end-markets.
Independent characterisation. PainChek has a defensible regulatory and clinical moat in a narrow niche, but its revenue base is sub-scale. Five years after reaching 100,000 contracted beds (June 2021), recognised customer revenue is A$3.74m. Average realised revenue per implemented licence is about A$49 per year (A$4.46m ARR ÷ 90,198 licences). The commercial model has historically depended on government funding: a A$5m Australian Government grant in 2019 subsidised early adoption. Converting signed licences into paying, implemented licences has been slower than management signalled. The board acknowledged in the FY2026 Annual Report that conversion "did not meet the Company's expectations in all areas." This led to a reset of reported KPIs in July 2026: signed but unimplemented licences are now reported as "pipeline" rather than contracted ARR, together with a CEO change. The investment case now rests almost entirely on US execution, under a newly installed US-based CEO, against a backdrop of going-concern uncertainty and a A$5.5m convertible note maturing in May 2027.
Strategy
Stated strategy (FY2026 Annual Report)
The Chair's letter frames FY2027 around "a sharper focus on conversion and execution." The company states it has "established the technology, regulatory access and commercial pathways," and that FY2027 is about converting those foundations into measurable commercial outcomes. The five stated FY2027 priorities are:
-
Implement faster: accelerate conversion of contracted and qualified opportunities into implemented licences and ARR.
-
Convert the US pipeline: move priority US pilots into deployments, focusing on larger long-term care, skilled nursing and memory-care groups.
-
Expand existing customers: increase licence implementation and utilisation within accessible customer groups, particularly in the UK.
-
Retain and grow the core: maintain retention and increase utilisation in ANZ.
-
Maintain commercial discipline: direct investment to opportunities that can generate implementation, utilisation and recurring revenue, reported against a focused set of measures.
Regional priorities (Annual Report)
-
UK and Ireland: "Existing Customers → Implementation → Recurring Revenue."
-
ANZ: "Retention – Utilisation – Expansion."
-
United States: "Qualified Pipeline – Deployment – Implemented Licences."
-
Canada: initial residential aged-care sales are in place, and the company is exploring additional aged-care and home-care partners.
Commercial model articulation: Market Access → Qualified Pipeline → Implementation → Implemented ARR → Customer Revenue and Receipts. PainChek now prioritises implemented ARR, retention and expansion over contracted licence counts.
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| FDA De Novo pathway | Submission Dec 2024; final submission 21 Jul 2025; granted 6 Oct 2025 | First FDA classification for AI pain-assessment software in non-communicative adults | Complete |
| North American operating base | FY2026 | Incorporation of PainChek Inc and PainChek Canada; US Head of BD hired (May 2025); US staff | Complete; continuing |
| Sabra Health Care REIT MSA | 14 Apr 2026 | Owner-funded licences across up to 329 facilities / 20,000 beds; Sabra required to introduce PainChek to current and future operators | First two 3-year contracts (Traditions) signed June 2026 |
| RTM reimbursement ("PainChek Plus") | Jan 2026 | Legal opinion that PainChek qualifies for RTM; PMPM model; planned launch at HIMSS March 2026 | No revenue disclosed |
| CMS-specific CPT code | Targeted by Apr 2026 | Application for a PainChek-specific code | Outcome not disclosed in sources reviewed |
| CMMI home-health programs (ACCESS, TEMPO) | Jan 2026 | Positioning for CMS Innovation Center-funded models | Exploratory |
| Mayo Clinic Platform | FY2026 | "Mayo Clinic Platform Accelerate" participation (Annual Report); qualification stage with Mayo Clinic Platform Solutions Studio (June 2026 4C) | In qualification |
| Silverado memory-care pilot | Jul 2026 | Initial pilot with a top-tier US memory-care operator | Pilot |
| Infant channel pivot | Jun 2026 quarter | Healthcare-professional and pharmacy recommendation channel replaces broad direct-to-consumer; SA pharmacy pilot from 1 Jul 2026 | Pilot |
| Platform Dashboard release | 8 Jul 2026 | Workflow, compliance and follow-up visibility for aged care and home care | Rolled out globally |
| KPI redefinition | Jul 2026 | Unimplemented contracts reclassified as pipeline; focus on implemented ARR | Adopted |
| Leadership refresh | May–Sep 2026 | New Chair, new US-based CEO, two long-serving directors departed | Complete |
| ROI evidence program | Jun 2026 | Casson Consulting UK ROI study: about 10p per bed per day, about 3.3% of the benefits | Published |
| European validations | 2,026 | Portuguese usability study; German validation; Spanish (Granada) infant scoping | In progress |
| Cost focus | FY2026–FY2027 | R&D refocused on core product; R&D payments down A$72k quarter on quarter in the June 2026 quarter | Ongoing |
Medium-term financial targets and guidance
PainChek has not issued quantitative revenue, ARR, EBITDA or cash-flow-breakeven guidance in the sources reviewed. Its targets are qualitative ("delivering growth in FY2027"). Market-sizing claims by management include:
-
US aged care: US$150m per year (1.5m people with dementia).
-
US home care: US$300m per year.
-
US RTM market: US$3.0bn by 2030 at a 17.2% CAGR, citing Data Bridge Market Research.
The company also claims US patent protection aligned to the RTM claims process "until 2038" (January 2026 business update). Previous timing guidance proved optimistic: FDA clearance was expected by mid-2024 (FNArena, September 2023), then the first half of calendar 2025 (H1 FY2025 report), then mid-to-late September 2025, and was received in October 2025.
ESG and sustainability commitments: none disclosed beyond information-security certifications (ISO 27001, SOC 2) and a Diversity and Inclusion policy (October 2024).
Products & Services
Adult segments (ANZ, UK, North America)
PainChek Adult App (flagship)
Description: A smartphone/tablet medical device app. AI-driven automated facial recognition and analysis identifies facial action units indicative of pain, and the carer adds structured observations of non-facial pain domains. Together these produce a pain-intensity score. Functions include pain assessment, pain monitoring, patient profiling and data synchronisation to a web portal (Atee, Hoti, Hughes et al., Frontiers in Aging Neuroscience, 2018).
Key capabilities: An assessment takes about three seconds of video capture (Stockhead, 2021). It works offline with later sync, records assessment history and trends, and documents for compliance and funding claims.
Regulatory status: Cleared in Australia (ARTG 302794), New Zealand, Canada, Singapore, Malaysia, the UK, the EU and the US. The US clearance is FDA De Novo DEN240073, granted 6 October 2025: Class II, prescription-only, adjunctive use, for conscious adults unable to communicate pain.
Target customer: Residential aged care, memory care, skilled nursing, home care and disability providers caring for people with moderate-to-severe dementia or other communication impairment.
Launch / latest version: First regulatory clearance 2017; major dashboard release 8 July 2026.
Pricing (disclosed): - UK: about 10p per bed per day, or about £3,650 per year for a 100-bed group (Casson Consulting / PainChek, June 2026).
-
US core SaaS: "US$50+ per bed per annum" (January 2026 business update).
-
Sabra MSA: US$55–75 per licence per annum, with lower pricing for longer terms or research participation (June 2026 4C).
PainChek Universal
Description: Combines the PainChek AI tool with the Numerical Rating Scale. Clinicians can assess people who can self-report, people who cannot, and those whose ability fluctuates, all in one app.
Launch: March 2021. CE-mark approval for the Universal version is referenced by Biotech Daily (2021).
Target customer: The same aged-care customers, extended to cognitively intact or fluctuating residents.
Pricing: Bundled within the subscription; separate pricing not disclosed.
PainChek Analytics
Description: A reporting suite and portal giving real-time dashboards and reports from frontline nurses to executives and boards. It covers pain trends, assessment compliance, follow-up gaps and treatment-effect monitoring.
Target customer: Clinical managers, quality leads and provider executives.
Pricing: Included in the subscription; not separately disclosed.
Adult Dashboard enhancement (July 2026 release)
Description: A redesigned in-app dashboard with real-time resident pain status. Adds two new views ("Follow-up Assessments" and "Routine Assessments") and configurable reassessment workflows tied to pain severity and risk. Flags positive pain assessments not followed up within policy timeframes. Also adds improved search and filtering, faster navigation, and online/offline status visibility.
Rollout: Global from 8 July 2026. Enabled by default for new customers; existing customers activate it after training.
Commercial significance: Management says the release contributed to new licence opportunities. Named endorsements came from Lutheran Services (Australia) and Perley Health (Canada).
PainChek Plus (US reimbursed model)
Description: A device-service agreement with qualified healthcare professionals (physiotherapists, physicians, occupational therapists, GPs) serving skilled nursing facilities. These professionals use PainChek to support billing of Remote Therapeutic Monitoring codes for musculoskeletal pain: CPT 98975 setup, 98985/98977 data capture, 98979/98980/98981 treatment management.
Pricing structures proposed (January 2026 deck): Model 1 is a fixed per-member-per-month (PMPM) fee. Model 2 is a lower PMPM plus revenue share. Management cites RTM claims of about US$150 per resident per month to providers.
Status: Planned launch at HIMSS (Las Vegas), March 2026. No revenue or contracts disclosed to date. The company also said it was pursuing a PainChek-specific CPT code with CMS by April 2026; the outcome was not disclosed in the sources reviewed.
Integration connectors
- About 40 integration partnerships with clinical systems globally (January 2026). Named partners include PointClickCare, Eldermark and Yardi (North America); Telstra Health (Australia); Leecare Solutions and Person Centred Software (UK); and TrakCare (hospital pilot, Edinburgh).
Purpose: PainChek runs inside clinical records already used by care teams, lowering implementation friction.
Implementation and training services ("Customer Excellence")
Description: Onboarding, training (including online learning and training registration), support and release management.
FY2026 revenue: A$138,352 (training and services).
Language variants
-
PainChek-PT (Portuguese): usability study published June 2026.
-
German-language version: validated by the University of Applied Sciences and Arts Bielefeld; manuscript in preparation.
-
A US validation in ethnically diverse dementia cohorts (African American, Hispanic/Latino, Asian) was being finalised for peer-reviewed publication (June 2026 4C).
Infant segment
PainChek Infant App
Description: A clinically validated app that detects six facial action units indicative of pain in infants aged 1 to 12 months (company boilerplate, July 2026).
Origin: The Murdoch Children's Research Institute "PainFaces" study, partnered July 2019.
Target customer: Parents, recommended by healthcare professionals and pharmacies.
Launch: April 2025 in Australia, direct to parents; marketing live from mid-2025.
Strategy change (June 2026 quarter): Shifted from broad direct-to-consumer marketing to healthcare-professional and pharmacy channels. Proposed added features are comforting strategies, a head-to-toe assessment, red-flag guidance and reassessment reminders.
Pilot: From 1 July 2026, 10–12 community pharmacies in South Australia, with a national pharmacy network (unnamed). The University of Granada is scoping a study on infant analgesic monitoring via pharmacies.
Pricing: Not publicly disclosed.
Revenue: A$293 in FY2026 (FY2025: A$935).
Addressable market (company claim): About A$15bn (October 2025 announcement). About 400m births per year, of which 150m are to first-time parents (Biotech Daily, October 2025).
- The FY2026 STI scorecard records that Infant App objectives were not achieved.
Financial Narrative
Income statement
Sources and notes
Revenue: FY2022 and FY2024 from StockAnalysis (aggregator). FY2023 is A$1.95m per FNArena's summary of the FY2023 preliminary report. FY2025 and FY2026 are audited customer revenue. FY2025 total revenue including interest is A$3,362,427.
R&D: FY2022 and FY2023 are "research expense" per the FY2023 preliminary report. FY2024 is from StockAnalysis (aggregator). FY2025 and FY2026 are audited.
Net losses: FY2022–FY2024 from the FY2026 remuneration report five-year table.
EBITDA definition: loss before tax, plus note interest, less interest income, plus depreciation. It includes R&D tax incentive income.
Operating income definition: customer revenue less all operating expenses, excluding other income.
Gross profit definition: customer revenue less cost of providing services. Aggregators use broader cost-of-revenue definitions and report much lower gross profit (StockAnalysis: FY2025 A$1.00m).
Revenue CAGR
The 3-year revenue CAGR from FY2023 to FY2026 is about 24.3%.
Margins
Management describes the business as having "80%+ gross margins" (January 2026 business update). That likely excludes implementation labour. The audited cost-of-service line implies about 70–71%.
Balance sheet
Sources and notes
Cash: FY2022–FY2024 from TipRanks (aggregator); FY2023 is also confirmed at A$2.51m by FNArena. FY2025 and FY2026 are audited.
FY2024 equity and accumulated losses: from the 1 July 2024 opening balances in the FY2025 statement of changes in equity.
Convertible notes: face value A$5.5m. Equity component of A$1.39m recognised in reserves.
R&D refund: the A$1.12m receivable is included in FY2026 receivables and was received on 22 July 2026.
Working capital: the going-concern note gives net current liabilities of A$63,478 (FY2025: A$1,132,464).
Unrecognised deferred tax assets: A$9.46m on tax losses at 25%. None are recognised on balance sheet.
Cash flow
Sources and notes
Free cash flow: FY2022–FY2024 from StockAnalysis (aggregator).
Financing cash flow: FY2022–FY2024 from TipRanks (aggregator).
FY2023 receipts: FNArena.
R&D refund timing: FY2026 operating cash flow received no R&D refund (FY2025: A$1.412m). The FY2025-year refund slipped into July 2026 (FY2027), which depresses FY2026 operating cash flow by about A$1.1m relative to FY2025.
Ratios
Why several ratios are n/a
-
ROE and debt to equity: equity is negative in FY2025 and FY2026.
-
ROIC: invested capital is negative.
-
Net debt to EBITDA: the company is in a net cash position with negative EBITDA.
-
Interest coverage: EBIT is negative.
-
The cash conversion cycle is not meaningful for an inventory-free subscription business. Customers prepay part of their subscriptions: contract liabilities were A$1.33m, about 36% of revenue.
Trend commentary
Revenue growth is decelerating sharply. Growth slowed from 97% (FY2023) to 37% (FY2024), 26% (FY2025) and 11% (FY2026), even as implemented licences grew 27.9% in FY2026. The gap reflects several factors:
-
Activations clustered late in the year, as shown by a 27% rise in June-quarter receipts.
-
Pricing mix: UK and pilot licences at lower rates, and US Sabra pricing at US$55–75.
-
Implemented ARR (A$4.46m) running ahead of recognised revenue.
The H1 FY2026 result showed customer revenue up only 5% to A$1.734m. That was the key inflection that preceded the board and CEO changes.
Cost base inflection. Total operating expenses rose from A$12.47m to A$13.66m in FY2026 (+9.5%):
-
Marketing and business development rose 25% to A$5.06m, for US/Canada sales set-up.
-
Corporate and administration rose 15% to A$3.70m, driven by Chair/CEO recruitment, US/Canada entity set-up, and higher legal, ASX and registry costs.
-
R&D fell 12% to A$3.32m after FDA clearance, as the company focused on the core product.
Losses. The net loss widened 16% to A$8.94m, the largest in five years after FY2024's A$8.31m. Two factors contributed: R&D tax incentive income fell from A$1.41m to A$1.12m, and a new A$0.20m note-interest charge was added. The interest charge accrues at a 54.7% effective rate under compound-instrument accounting; cash interest is 12%.
Balance sheet. Equity has been negative since FY2025. Cash of A$5.99m at 30 June 2026 was funded almost entirely by capital raised during FY2026: A$13.6m net, made up of a A$7.5m placement, A$1.09m of option exercises and the A$5.5m notes. The June 2026 Appendix 4C reported about 3.3 quarters of funding at the June-quarter burn rate (A$1.79m), before the A$1.12m R&D refund.
Funding dependency. Over FY2022–FY2026, cumulative free cash flow was about -A$36.5m and cumulative financing inflows about A$31.1m (partly aggregator data). PainChek has never generated positive operating cash flow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents |
|---|---|
Adult ANZ | PainChek Adult / Universal app, Analytics, implementation and training sold to aged-care, home-care and disability providers in Australia and New Zealand |
Adult UK | Same products in the United Kingdom (including Scotland) via PainChek UK Limited |
Adult North America | Same products in the US and Canada (PainChek Inc, PainChek Canada Limited). FDA-cleared PainChek Adult; Sabra MSA; RTM model. |
Infant ANZ | PainChek Infant app (direct-to-parent, then healthcare-professional/pharmacy channel) |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Adult ANZ revenue (AUD Mn) | — | 2.164 | 2.284 |
Adult UK revenue (AUD Mn) | — | 1.193 | 1.415 |
Adult North America revenue (AUD Mn) | — | 0.000 | 0.044 |
Infant ANZ revenue (AUD Mn) | — | 0.001 | 0.000 |
Total customer revenue (AUD Mn) | 2.67 | 3.358 | 3.742 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2025–FY2026)
| Segment | FY2025 | FY2026 |
|---|---|---|
Adult ANZ contribution (AUD Mn) | -0.044 | 0.612 |
Adult UK contribution (AUD Mn) | -0.978 | -0.844 |
Adult North America contribution (AUD Mn) | -0.058 | -1.530 |
Infant ANZ contribution (AUD Mn) | -0.399 | -0.503 |
Total segment contribution (AUD Mn) | -1.479 | -2.264 |
Segment Revenue
| Segment | FY2025 contribution margin (%) | FY2026 contribution margin (%) | FY2026 revenue YoY (%) | FY2025 share of revenue (%) | FY2026 share of revenue (%) |
|---|---|---|---|---|---|
Adult ANZ | -2.1 | 26.8 | 5.6 | 64.4 | 61.0 |
Adult UK | -82.0 | -59.6 | 18.6 | 35.5 | 37.8 |
Adult North America | n/m | n/m | n/m | 0.0 | 1.2 |
Infant ANZ | n/m | n/m | -68.7 | 0.0 | 0.0 |
Segment Overview — Adult ANZ
| Segment | Revenue | Cost of providing services | Marketing and BD | Contribution |
|---|---|---|---|---|
Adult ANZ | 2,283,670 | (406,016) | (1,265,753) | 611,901 |
Adult UK | 1,414,524 | (556,168) | (1,701,860) | (843,504) |
Adult North America | 43,584 | (140,717) | (1,433,033) | (1,530,166) |
Infant ANZ | 293 | (32) | (502,910) | (502,649) |
Total | 3,742,071 | (1,102,933) | (4,903,556) | (2,264,418) |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Customer revenue (AUD Mn) | 0.99 | 1.95 | 2.67 | 3.36 | 3.74 |
Revenue growth (%) | 325.1 | 96.7 | 36.6 | 25.8 | 11.4 |
Subscription revenue (AUD Mn) | — | — | — | 3.14 | 3.60 |
Training and services revenue (AUD Mn) | — | — | — | 0.22 | 0.14 |
R&D tax incentive and grants, other income (AUD Mn) | — | — | — | 1.44 | 1.15 |
Cost of providing services (AUD Mn) | — | — | — | 0.97 | 1.10 |
Gross profit, company basis (AUD Mn) | — | — | — | 2.39 | 2.64 |
Research and development expense (AUD Mn) | 2.35 | 3.49 | 4.57 | 3.78 | 3.32 |
Marketing and business development expense (AUD Mn) | — | — | — | 4.04 | 5.06 |
Corporate and administration expense (AUD Mn) | 2.78 | 3.36 | — | 3.22 | 3.70 |
Share-based payments expense (AUD Mn) | 0.55 | — | — | 0.47 | 0.47 |
Operating income, excluding other income (AUD Mn) | — | — | — | -9.12 | -9.92 |
EBITDA (AUD Mn) | — | — | — | -7.66 | -8.75 |
Pre-tax income (AUD Mn) | -5.72 | -7.57 | -8.31 | -7.67 | -8.94 |
Net income (AUD Mn) | -5.72 | -7.57 | -8.31 | -7.67 | -8.94 |
EPS basic, as reported (A$ cents) | -5.1 | -5.9 | -5.7 | -0.44 | -4.3 |
EPS diluted, as reported (A$ cents) | -5.1 | -5.9 | -5.7 | -0.44 | -4.3 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Revenue CAGR from FY2022 (%) | 97.0 | 64.2 | 50.6 | 39.4 |
Margin Analysis (%) (FY2022–FY2026)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin, company basis (%) | — | — | — | 71.2 | 70.5 |
Operating margin, excluding other income (%) | — | — | — | -271.6 | -265.0 |
EBITDA margin (%) | — | — | — | -228.1 | -233.8 |
Net margin (%) | -577.8 | -388.2 | -311.2 | -228.4 | -238.8 |
R&D as share of revenue (%) | 237.4 | 179.0 | 171.2 | 112.5 | 88.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 6.14 | 2.51 | 3.56 | 1.62 | 5.99 |
Trade and other receivables (AUD Mn) | — | — | — | 0.51 | 1.61 |
Total assets (AUD Mn) | — | — | — | 2.15 | 7.63 |
Short-term debt, convertible notes at carrying value (AUD Mn) | 0 | 0 | 0 | 0 | 4.25 |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Total debt (AUD Mn) | 0 | 0 | 0 | 0 | 4.25 |
Net debt, negative means net cash (AUD Mn) | -6.14 | -2.51 | -3.56 | -1.62 | -1.74 |
Contract liabilities, deferred revenue (AUD Mn) | — | — | — | 1.07 | 1.33 |
Total liabilities (AUD Mn) | — | — | — | 3.26 | 7.67 |
Total equity (AUD Mn) | — | — | 1.29 | -1.11 | -0.04 |
Goodwill and intangibles (AUD Mn) | — | — | — | 0 | 0 |
Working capital (AUD Mn) | — | — | — | -1.13 | -0.06 |
Accumulated losses (AUD Mn) | — | — | -56.89 | -64.56 | -73.50 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | 2.24 | — | 3.52 | 4.00 |
Operating cash flow (AUD Mn) | — | — | — | -6.75 | -9.24 |
Capex (AUD Mn) | — | — | — | 0.01 | 0.01 |
Free cash flow (AUD Mn) | -7.02 | -6.34 | -7.16 | -6.77 | -9.25 |
Financing cash flow (AUD Mn) | 1.75 | 2.70 | 8.21 | 4.82 | 13.64 |
Equity raised (AUD Mn) | — | — | — | 4.82 | 8.14 |
Convertible notes raised (AUD Mn) | 0 | 0 | 0 | 0 | 5.50 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
ROA, on average assets (%) | — | -182.7 |
Current ratio (x) | 0.65 | 0.99 |
Asset turnover, on average assets (x) | — | 0.77 |
Days sales outstanding, trade receivables (days) | 48 | 37 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue (AUD Mn) | — | 2.137 | 2.182 |
United Kingdom revenue (AUD Mn) | — | 1.193 | 1.415 |
Other countries revenue (AUD Mn) | — | 0.027 | 0.146 |
Total revenue (AUD Mn) | 2.67 | 3.358 | 3.742 |
Revenue by Region (%)
| Region (%) | FY2026 YoY growth (%) | FY2026 share (%) |
|---|---|---|
Australia | 2.1 | 58.3 |
United Kingdom | 18.6 | 37.8 |
Other countries (NZ, US, Canada) | 432.1 | 3.9 |
Segment Overview — Adult
| Segment | Australia | New Zealand | United Kingdom | US/Canada |
|---|---|---|---|---|
Adult (AUD Mn) | 2.182 | 0.102 | 1.415 | 0.044 |
Infant (AUD Mn) | 0.000 | 0.000 | 0.000 | 0.000 |
Operating Metrics (number) and Revenue by Region
| Region | Mar-2026 | Jun-2026 |
|---|---|---|
ANZ implemented licences (number) | 53,904 | 55,246 |
UK implemented licences (number) | 30,082 | 33,470 |
North America implemented licences (number) | 1,214 | 1,482 |
Total implemented licences (number) | 85,200 | 90,198 |
ANZ implemented ARR (AUD Mn) | 2.47 | 2.54 |
UK implemented ARR (AUD Mn) | 1.68 | 1.85 |
North America implemented ARR (AUD Mn) | 0.06 | 0.07 |
Total implemented ARR (AUD Mn) | 4.21 | 4.46 |
Revenue by Region and Operating Metrics (number)
| Metric | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|---|---|
Implemented ARR (AUD Mn) | 3.3 | 3.4 | 3.58 | 3.5 | 3.7 | 4.21 | 4.46 |
Contracted ARR, when fully implemented (AUD Mn) | 4.8 | 4.9 | 5.5 | 5.6 | 5.6 | 5.9 | — |
Implemented licences (number) | 68,458 | 71,088 | 70,539 | 71,751 | 75,590 | 85,200 | 90,198 |
Share Price and Share Count (m)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.28 | 0.25 | 0.27 | 0.45 | 0.10 |
Shares on issue at 30 June, post-consolidation basis (m) | — | — | 163.6 | 184.2 | 209.0 |
Market capitalisation at 30 June (AUD Mn) | — | — | 44.2 | 82.9 | 20.9 |
Performance Window Details
| Performance window | Return (%) | Basis |
|---|---|---|
1-year (30 Jun 2025 – 30 Jun 2026) | -77.8 | A$0.45 to A$0.10 |
3-year (30 Jun 2023 – 30 Jun 2026) | -60.0 | A$0.25 to A$0.10 |
4-year (30 Jun 2022 – 30 Jun 2026) | -64.3 | A$0.28 to A$0.10 |
From post-FDA peak (10 Oct 2025, about A$0.80 adjusted) | About -87 | Biotech Daily, Oct 2025; adjusted from A$0.08 pre-consolidation |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | About A$20.9m | 209.0m shares × A$0.10 |
Enterprise value | About A$19.2m (carrying debt) to A$20.4m (face value) | Plus notes A$4.25m carrying / A$5.5m face, less cash A$5.99m (30 June 2026) |
EV / Sales (FY2026) | About 5.1–5.5x | A$3.74m customer revenue |
EV / Implemented ARR | About 4.3–4.6x | A$4.46m |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
P/B | n/m | Negative book equity (-A$0.04m) |
Peer multiples | Not publicly available for comparable direct peers | No listed direct competitors |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | Never paid; no dividends or capital returns in the last 5 years. No franking credits available. |
Dividend policy | None; loss-making |
Buybacks | None authorised or executed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Bank facilities | None (Appendix 4C, section 7: no loan or standby facilities) |
Capital Markets Data
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
Convertible notes face value maturing (AUD Mn) | 0 | 5.5 | 0 |
Share Price & Returns
| Date | Instrument | Price | Proceeds |
|---|---|---|---|
Dec 2024 – Mar 2025 | Entitlement offer and placement | A$0.025 pre-consolidation (A$0.25 adjusted) | About A$5.12m gross |
Jul–Aug 2025 | Placement (22.06m post-consolidation shares) | A$0.034 pre-consolidation (A$0.34 adjusted) | A$7.5m gross |
FY2026 | Option exercises (2.22m shares) | A$0.50 adjusted | A$1.09m |
May 2026 | Convertible notes | Conversion at A$0.195 | A$5.5m |
Analyst Conclusions
Management guidance
No quantitative guidance. Management's qualitative outlook for FY2027 (Annual Report and June 2026 4C) has four parts:
-
Accelerate revenue growth.
-
Convert qualified opportunities into implemented licences.
-
Expand utilisation within existing customers.
-
Execute partnerships, chiefly Sabra, that can scale market access.
These priorities are to be pursued "with a strengthened balance sheet." Management also said June-quarter staff savings are not indicative of the future cost base.
Consensus growth expectations
No reliable consensus exists (see 21.3). An analyst reference point, not a forecast: entering FY2027 with A$4.46m of implemented ARR, FY2027 recognised revenue should exceed FY2026's A$3.74m on run-rate alone. Implemented ARR exceeds FY2026 revenue by about 19%.
Bull case (grounded in data)
-
The Sabra template scales. Converting even half of Sabra's up to 20,000 beds at US$55–75 adds roughly US$0.55–0.75m of ARR. Replicating the owner-funded model with other healthcare REITs could multiply North American ARR (A$0.07m today) several-fold with limited sales cost.
-
A US-specialist leadership team fixes conversion. Holzberger's Nuance and GE Healthcare commercial background is the right profile for US enterprise selling. With ANZ already contribution-positive (A$0.61m) and the UK growing about 19%, US traction plus RTM reimbursement could re-rate a stock trading at about 4–5x EV/ARR.
-
Embedded clinical product with a moat. Retention of 85–93%, 22m+ assessments, FDA De Novo first-mover status and about 40 EHR integrations make PainChek a logical acquisition target for an EHR or aged-care platform. The roughly A$20m equity value is small relative to the regulatory and data assets.
Bear case (grounded in data)
-
Refinancing overhang. At 30 June 2026 the company had A$5.99m cash, an operating burn of A$1.79m in the June quarter, and A$5.5m of notes due in May 2027 with conversion about 95% above the current price. A dilutive equity raise or note restructuring in the next 6–9 months looks highly probable. The auditor's going-concern emphasis of matter underlines this.
-
Conversion has repeatedly disappointed. Revenue growth fell from 97% to 11% over three years. Contracted ARR (A$5.9m) was never realised before the KPI was abandoned. US revenue was only A$44k in the first year after FDA clearance despite A$1.43m of segment marketing spend.
-
Low price point and free substitutes cap the economics. Implemented ARR of about A$49 per licence, competing with free scales (Abbey, PAINAD), means even large licence wins produce small revenue. The RTM model (PainChek Plus) and the CMS code remain unproven, with no disclosed revenue.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable | What to watch |
|---|---|---|
| By late Oct 2026 | September 2026 quarter 4C (first under new CEO) | Implemented ARR (above A$4.46m?), North American licences, receipts, cash burn, cash balance including the A$1.12m refund |
| 4 Nov 2026 | AGM | CEO strategy; votes on Chair/NED equity and remuneration; any capital-management resolutions (note options, placement capacity) |
| Q2 FY2027 | Sabra network conversions | Number of additional operators and facilities signed and implemented |
| Q2–Q3 FY2027 | RTM / PainChek Plus | First reimbursed contracts; CMS CPT-code status |
| Q2–Q3 FY2027 | Mayo Clinic Platform qualification; Silverado pilot conversion | Progression to commercial terms |
| Late Feb 2027 | H1 FY2027 results | Revenue growth re-acceleration versus H1 FY2026's +5% |
| Before May 2027 | Convertible note maturity (A$5.5m) | Refinancing, redemption or restructuring; equity raise size and price |
| FY2027 | Infant pharmacy pilot readout | Go/no-go on broader infant investment |
| FY2027 | Board renewal | Additional NED appointments; creation of audit and remuneration committees |
| FY2027 | Peer-reviewed US diverse-cohort publication; German validation | Evidence for US and EU adoption |
Concluding analyst verdict
PainChek has built something genuinely rare: a clinically validated, multi-jurisdiction-cleared AI medical device that addresses a real and under-served problem. It has an FDA De Novo classification that no competitor holds, a customer base that rarely leaves, and usage that is compounding faster than revenue. Assessments grew 76% in FY2026; revenue grew 11%. The business is not short of product-market validation. It is short of commercial throughput and capital.
The FY2026 accounts are sobering. Revenue of A$3.74m against an operating cost base of A$13.7m, negative equity, and a going-concern emphasis of matter mean PainChek remains a funding-dependent company ten years after listing. The board's own language is unusually candid about conversion falling short. It drove an overhaul in mid-2026: a new Chair, a US-based CEO, the departure of two founding-era directors and the abandonment of the "contracted ARR" metric in favour of implemented ARR. Investors should welcome the more honest scorecard. It also confirms that earlier headline metrics overstated near-term revenue.
The investment question for the next 12 months is binary. Either the new leadership converts US access into a visible, repeatable revenue engine fast enough to refinance the May 2027 notes on acceptable terms, or the company raises equity from a position of weakness. The Sabra owner-funded model is the most promising proof point, and Holzberger's profile fits the task. However, the September and December 2026 quarterlies must show North American licences moving from the low thousands toward the tens of thousands.
At about A$20m of market value and about 4–5x implemented ARR, the equity prices in significant execution and dilution risk. That pricing creates asymmetric upside if US conversion and RTM materialise, or if a strategic acquirer values the regulatory and data assets. Until conversion is demonstrated and the balance sheet is repaired, PainChek is a speculative, catalyst-driven holding. Position sizing should assume a further capital raise.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / education | FY2026 total remuneration |
|---|---|---|---|---|
Karen Holzberger | Chief Executive Officer (US-based) | From 17/18 Aug 2026 (date differs between July announcement and Annual Report) | 26 years in healthcare leadership. Most recently President and CEO of SpinTech MRI (FDA-cleared STAGE MRI software). Previously SVP and GM, Nuance Healthcare Diagnostic Division (Nuance was acquired by Microsoft for about US$19.7bn in 2022). Before that, VP and GM, GE Healthcare Global Radiology Workflow. B.S. Mechanical Engineering, Stevens Institute of Technology. Age not disclosed. | Not applicable for FY2026. Package: US$387,000 per year fixed, plus STI/LTI eligibility (terms to be set by the board), 3-month notice. |
Andrew (Andy) Hoggan | Chief Operating Officer (Interim CEO 6 Jul – 17 Aug 2026) | Start date not disclosed | — | Not a disclosed KMP |
Iain McAdam | Chief Financial Officer | Since 22 Mar 2021 | Not detailed in sources reviewed | A$323,767 (base A$245,211; cash bonus A$18,897; options A$21,403; super A$31,122; long-service leave A$7,134) |
Prof. Jeff Hughes | Chief Scientific Officer | Co-founder (Curtin University) | Pharmacist-academic; co-inventor of ePAT | Not disclosed (not KMP) |
Prof. Kreshnik Hoti | — | Co-founder researcher | Co-inventor; lead author of 2026 Age and Ageing and Frontiers papers | — |
Tandeep Gill | General Manager and Head of Business Development, UK | — | — | — |
David Allsopp | Head of Business Development, ANZ | — | — | — |
Natalie Climo | Company Secretary (Boardroom) | Since 19 Jan 2024 | LLB, GDLP; 15 years' corporate experience | Paid via company secretarial fees (A$73,868 in FY2026) |
Philip Daffas (former) | CEO and Managing Director | 30 Sep 2016 – 6 Jul 2026 (employment ended 6 Oct 2026) | BSc, Dip EEng, MBA, GAICD. About 30 years in diagnostics (Roche/Boehringer Mannheim, UK and Germany). | A$449,450 (base A$244,099; STI A$18,000 of a possible A$150,000; performance rights A$136,455; super A$28,417; long-service leave A$22,479) |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Independence (analyst view) | Background | FY2026 total remuneration (AUD) |
|---|---|---|---|---|---|
Lil Bianchi | Non-Executive Chair | 25 May 2026 | Independent | BSc(Econ), MSc Computer Science, GAICD. Chair of 4DMedical (ASX: 4DX); NED of Qscan Radiology Group and Murrumbidgee Irrigation. | 16,667 |
John Murray | Non-Executive Director (Chair 2016–May 2026) | 30 Sep 2016 | Independence weakened by 10-year tenure as former Chair | LLB (Hons), CA, MAICD. Co-founder of Technology Venture Partners. Director of Seeing Machines (AIM). Former Viator director. | 137,494 |
Adam Davey | Non-Executive Director | 30 Sep 2014 (pre-RTO MinQuest board) | Questionable: Director of Wealth Management at Canaccord Genuity Patersons, a broker; 12-year tenure | Capital markets, ASX listings, M&A. NED of The Agency Group Australia. | 70,413 |
Cynthia Payne | Non-Executive Director | 30 Mar 2022 | Independent | MBA, B.App.Sci (Nursing). Founder of Anchor Impact Group. Aged-care governance credentials. | 70,413 |
Major Shareholders
| Holder | Shares | % of 209.0m shares | Performance rights |
|---|---|---|---|
Philip Daffas (former CEO) | 3,114,226 | 1.49 | 1,276,358 |
John Murray | 1,854,460 | 0.89 | 96,852 |
Adam Davey | 1,606,658 | 0.77 | 48,426 |
Ross Harricks (departed) | 1,180,727 | 0.56 | 48,426 |
Cynthia Payne | 369,588 | 0.18 | 48,426 |
Lil Bianchi | 0 | 0.00 | 0 (to be approved) |
Iain McAdam (CFO) | 54,176 | 0.03 | 400,000 options |
Total directors at 30 June 2026 | 8,125,659 | 3.89 | 1,518,488 |
Current board only (Bianchi, Murray, Davey, Payne) | 3,830,706 | 1.83 | — |
Competitive Landscape
Key Competitors
| Competitor / substitute | Category | Segment overlap | Relative positioning |
|---|---|---|---|
Abbey Pain Scale | Observational pain scale (free) | Adult ANZ/UK | Australian standard before PainChek. Dr Jennifer Abbey is now a PainChek advisor. Zero cost, but subjective. |
PAINAD (Pain Assessment in Advanced Dementia) | Observational scale (free) | Adult US/global | Widely used in US nursing homes; PainChek must displace it inside EHR workflows |
PACSLAC-II | Observational checklist | Adult (Canada/global) | Comprehensive but time-consuming |
DOLOPLUS-2 | Observational scale | Adult (Europe) | Incumbent in parts of continental Europe |
NOPAIN (Non-Communicative Patient's Pain Assessment Instrument) | Observational scale | Adult | Legacy instrument |
FLACC / NIPS infant scales | Observational scales | Infant | Clinical standard for infant pain; free |
PointClickCare | Long-term-care EHR (private) | Adult North America | Integration partner. Hosts scales natively, so it could build a competing feature. |
MatrixCare | Long-term-care EHR | Adult US | Embeds standard assessments; no disclosed PainChek integration |
Person Centred Software | UK digital care records (private) | Adult UK | Integration partner and channel; also a potential substitute |
SafelyYou | AI video monitoring, US memory care (private) | Adult US (budget competition) | Competes for memory-care technology spend and AI-monitoring mindshare |
Hinge Health | Digital MSK / RTM (listed in the US) | US reimbursement model | Established RTM biller; competes for MSK RTM economics, not dementia pain assessment |
Sword Health | Digital MSK / RTM (private) | US reimbursement model | As above |
Competitor Detail
| Metric | PainChek (FY2026) |
|---|---|
Revenue | A$3.74m |
Revenue growth | 11.4% |
Gross margin | 70.5% (company basis) |
Net margin | -238.8% |
R&D intensity | 88.8% of revenue |
Regulatory status for pain assessment | FDA De Novo, TGA, CE/UKCA, Health Canada and others |
Recent Developments
The June 2026 quarter noted lower staff payments from "staff changes, short-term vacancies and timing," which management said is not indicative of the future cost base.



